Edgar Filing: NANOGEN INC - Form 8-K

NANOGEN INC Form 8-K November 30, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 27, 2007

NANOGEN, INC.

(Exact name of registrant specified in its charter)

Delaware (State or other jurisdiction of incorporation)

000-23541 (Commission File Number) 33-0489621 (I.R.S. Employer Identification No.)

10398 Pacific Center Court, San Diego, California (Address of principal executive offices)

Registrant s telephone, including area code: (858) 410-4600

92121 (Zip Code)

(Former name and former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: NANOGEN INC - Form 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 27, 2007, Nanogen, Inc. (the Company) received a letter from the NASDAQ Stock Market advising that for the previous 30 consecutive business days, the bid price of the Company s common stock (the Common Stock) had closed below the minimum \$1.00 per share requirement for continued inclusion on the NASDAQ Global Market pursuant to NASDAQ Marketplace Rule 4450(a)(5). This notification has no effect on the listing of the Common Stock at this time.

NASDAQ stated in its letter that in accordance with NASDAQ Marketplace Rule 4450(e)(2), the Company will be provided 180 calendar days, or until May 27, 2008, to regain compliance with the minimum bid price requirement. The NASDAQ letter also states that if, at any time before May 27, 2008, the bid price of the Common Stock closes at \$1.00 per share or more for a minimum of 10 consecutive business days, the NASDAQ staff will provide the Company with written notification that it has achieved compliance with the minimum bid price requirement.

If the Company does not regain compliance with the minimum bid price requirement by May 27, 2008, the NASDAQ staff will provide the Company with written notification that the Common Stock will be delisted from the NASDAQ Global Market. At that time, the Company may appeal the delisting determination to a NASDAQ Listings Qualifications Panel pursuant to applicable NASDAQ rules. Alternatively, NASDAQ Marketplace Rule 4450(i) may permit the Company to transfer the Common Stock to the NASDAQ Capital Market if the Common Stock satisfies all criteria, other than compliance with the minimum bid price requirement, for initial inclusion on such market. In the event of such a transfer, the NASDAQ Marketplace Rules provide that the Company will be afforded an additional 180 calendar days to comply with the minimum bid price requirement while listed on the NASDAQ Capital Market.

On November 30, 2007, the Company issued the press release attached to this Current Report as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

- (d) Exhibits. The following document is filed as an exhibit to this report:
 - 99.1 Press Release of Nanogen, Inc., dated November 30, 2007

Edgar Filing: NANOGEN INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NANOGEN, INC.

Date: November 30, 2007 By: /s/ Robert Saltmarsh

Name: Robert Saltmarsh Title: Chief Financial Officer